(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 120.95% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.81%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Nyxoah Sa's revenue in 2025 is $6,556,976.On average, 11 Wall Street analysts forecast NYXH's revenue for 2025 to be $304,262,913, with the lowest NYXH revenue forecast at $257,557,205, and the highest NYXH revenue forecast at $368,539,580. On average, 11 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,208,153,540, with the lowest NYXH revenue forecast at $823,131,801, and the highest NYXH revenue forecast at $1,899,878,604.
In 2027, NYXH is forecast to generate $2,774,972,382 in revenue, with the lowest revenue forecast at $2,281,220,954 and the highest revenue forecast at $3,211,918,555.